|Price and Volume|
|52 Week High||9.50|
|52 Week Low||1.51|
|Avg. Daily Vol. (Mil)||0.17|
|Beta (3 year)||-0.70|
|Share Related Items|
|Mkt Cap (Mil)||43.83|
|Shares Out (Mil)||16.92|
|LT Debt/ Equity||0.00|
|Total Debt / Equity||0.12|
|Per Share Data|
|Novogen Ltd is in the early stage of drug development.|
|16-20 Edgeworth David Avenue
Sydney, NS 2077
|Industry : Drugs|
|Sector: Health Care|
|CEO: Dr. Graham E. Kelly|
|Current Month (Mil)||0.04|
|Previous Month (Mil)||0.06|
|Short Interest Ratio (Days)||0.50|
|Return on Equity||n.a.|
|Return on Assets||0.00|
|Return on Investments||n.a.|
|Rating||Current||1-Mo Ago||2-Mo Ago||3-Mo Ago|
|GET NVGN ANALYST REPORT|
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Chris Versace, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.
Master swing trader Alan Farley uses his sophisticated software screens to review thousands of stocks each day for you, to find just the handful that meet his demanding criteria.